Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LE7P
|
|||
| Former ID |
DIB014198
|
|||
| Drug Name |
SDZ-GLC-756
|
|||
| Synonyms |
GLC-756; SDZ GLC 756; SCHEMBL14392424; BDBM85047; PDSP1_000850
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Glaucoma/ocular hypertension [ICD-11: 9C61; ICD-9: 365] | Discontinued in Phase 1 | [1] | |
| Company |
Novartis AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H24N2S
|
|||
| Canonical SMILES |
CN1CC(CC2C1CC3=CC=CC=C3C2)CSC4=CC=CC=N4
|
|||
| InChI |
1S/C20H24N2S/c1-22-13-15(14-23-20-8-4-5-9-21-20)10-18-11-16-6-2-3-7-17(16)12-19(18)22/h2-9,15,18-19H,10-14H2,1H3/t15-,18-,19-/m1/s1
|
|||
| InChIKey |
JVCCQRRESBKGJS-ATZDWAIDSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008736) | |||
| REF 2 | SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors. J Neural Transm. 1996;103(1-2):17-30. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.